TEENs Study Shows Achieving Target Blood Sugar Levels is Associated with Better Quality of Life for Young People with Type 1

   TEENs Study Shows Achieving Target Blood Sugar Levels is Associated with
         Better Quality of Life for Young People with Type 1 Diabetes

  PR Newswire

  PARIS, June 16, 2014

PARIS, June 16, 2014 /PRNewswire/ --

  − Findings set foundation to drive recommendations for enhancing care − 

Sanofi (EURONEXT: SANand NYSE: SNY) announced today the first results of the
TEENs Registry Study, the largest contemporary real-world study of the care of
nearly 6,000 young people with type 1 diabetes, ages 8 to 25. The findings not
only highlighted that over 70% of youths are not attaining their blood sugar
target levels (measured by HbA [1C] ), but also that achieving target HbA [1]
[C] is associated with a significantly better quality of life (QoL) for young
people (p<0.05).

The TEENs Study investigated factors associated with better blood sugar
control (defined as achieving target HbA [1] [C] levels recommended by
international organizations) and QoL per age class, with three predefined age
groups of 8-12, 13-18, and 19-25 years. The key factors identified were a
younger age (8 to 12 years), balanced family support for diabetes management,
and absence of family financial burden related to diabetes. The TEENs Study
findings will help set a foundation for recommendations to enhance care aimed
at improving disease management and patient outcomes. The findings were
presented at the 74 ^th Scientific Sessions of the American Diabetes
Association in San Francisco.

" The TEENs S tudy provides exceptional, contemporary data related to the care
and outcomes of young people with type 1 diabetes from around the globe. In
particular,  the study  aimed at identifying modifiable barriers to diabetes
management, especially during the transition from pediatric to adult care ,
and is providing an assessment of the challenges facing teens with type 1
diabetes and a unique view of young adults, " said Lori Laffel MD MPH,
Associate Professor/Chief of the Pediatric, Adolescent and Young Adult Section
of the Joslin Diabetes Center, Harvard Medical School, Boston, U.S. and
Co-Chair of the TEENs Registry Study Steering Committee. " The findings from
the TEENs S tudy can help us to design new approaches to care that can
overcome many of the challenges associated with suboptimal glycemic control
and psychosocial burdens of care in order to help young people with type 1
diabetes and their families. "

" Sanofi is committed to advanci ng knowledge in type 1 diabetes  to improve
disease management and outcomes, " said Pierre Chancel, Senior Vice President,
Global Diabetes, Sanofi. " Overall,  insights from TEENS  give us a unique
opportunity to better assess the unmet needs of  c hildren, teens and young
adults with type 1 diabetes, thereby enhancing their  glycemic  control and
quality of life  as well as  limit ing their  risk of long - term
complications . "

Sanofi has partnered with more than 200 clinics, centers and hospitals,
notably with the T1D Exchange in the US, for interviewing healthcare
providers, youths with type 1 diabetes, and their families in 20 countries
(within Europe, the US, Latin America, Middle East, North Africa, South
Africa, India). The results showed that achieving target HbA [1] [C] was
associated with a significantly better QoL (p<0.05) in a real life setting.
The TEENs Study findings also showed that over 70% of people aged 8 to 25
years were not achieving their HbA [1] [C] target according to international
guidelines, with only 32% of 8 to 12 year olds and 29% of 13 to 18 year olds
(ISPAD guidelines), and 19% of 19 to 25 year olds (ADA guidelines) reaching
HbA [1] [C] targets.

Furthermore, the TEENs findings suggest that young people with type 1 diabetes
can increase their chances of reaching their target HbA [1C] levels and having
a better QoL by modifying approaches to diabetes management and education,
such as using advanced intensive insulin regimens, performing frequent blood
sugar monitoring (more than three times a day), engaging in regular exercise,
and attending to dietary management. Family support has also been identified
as a key factor influencing glycemic control (family involvement, absence of
diabetes-specific family conflicts), as well as maintaining parental working
activities, which was also linked to better QoL for young people with type 1
diabetes. Absence of financial burden related to diabetes was also associated
with better glycemic control and QoL for young people with type 1 diabetes.

The TEENs abstracts are titled:

1.Global Assessment of Factors Associated with Target Glycemic Control in
    Youth with Type 1 Diabetes (T1D): the TEENs Study (Laffel et al. Oral
    presentation, June 13, 6:00 pm PST, abstract # 32-OR) 
2.Opportunities to Enhance Diabetes-specific Quality of Life (QoL) in Youth
    with Type 1 Diabetes (T1D): the Global TEENs Study (Anderson et al. Oral
    presentation, June 16, 9:00 am PST, abstract # 259-OR) 
3.Diabetes-specific Health-related Quality of Life (QoL) in a Sample of US
    Youth with Type 1 Diabetes (T1D) in the TEENs Study (Anderson et al.
    Poster presentation, June 14, 11:30 am to 1:30 pm PST, abstract # 1247-P)

About Sanofi 

Sanofi, a global healthcare leader, discovers, develops and distributes
therapeutic solutions focused on patients' needs. Sanofi has core strengths in
the field of healthcare with seven growth platforms: diabetes solutions, human
vaccines, innovative drugs, consumer healthcare, emerging markets, animal
health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in
New York (NYSE: SNY).

Forward Looking Statements 

Sanofi Forward Looking Statements 

This press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, as amended. Forward-looking
statements are statements that are not historical facts. These statements
include projections and estimates and their underlying assumptions, statements
regarding plans, objectives, intentions and expectations with respect to
future financial results, events, operations, services, product development
and potential, and statements regarding future performance. Forward-looking
statements are generally identified by the words "expects", "anticipates",
"believes", "intends", "estimates", "plans" and similar expressions. Although
Sanofi's management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned that
forward-looking information and statements are subject to various risks and
uncertainties, many of which are difficult to predict and generally beyond the
control of Sanofi, that could cause actual results and developments to differ
materially from those expressed in, or implied or projected by, the
forward-looking information and statements. These risks and uncertainties
include among other things, the uncertainties inherent in research and
development, future clinical data and analysis, including post marketing,
decisions by regulatory authorities, such as the FDA or the EMA, regarding
whether and when to approve any drug, device or biological application that
may be filed for any such product candidates as well as their decisions
regarding labelling and other matters that could affect the availability or
commercial potential of such product candidates, the absence of guarantee that
the product candidates if approved will be commercially successful, the future
approval and commercial success of therapeutic alternatives, the Group's
ability to benefit from external growth opportunities, trends in exchange
rates and prevailing interest rates, the impact of cost containment policies
and subsequent changes thereto, the average number of shares outstanding as
well as those discussed or identified in the public filings with the SEC and
the AMF made by Sanofi, including those listed under "Risk Factors" and
"Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual
report on Form 20-F for the year ended December 31, 2013. Other than as
required by applicable law, Sanofi does not undertake any obligation to update
or revise any forward-looking information or statements. 

Contact: Contacts: Media Relations: Jack Cox, Tel.: +(33)-1-53-77-46-46,
jack.cox@sanofi.com; Investor Relations: Sébastien Martel, Tel.:
+(33)-1-53-77-45-45, ir@sanofi.com; Global Diabetes Communications: Tilmann
Kiessling, Mobile: +49-17-26-15-92-91, Tilmann.kiessling@sanofi.com.
Press spacebar to pause and continue. Press esc to stop.